Cartesian Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.6%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$552.3Knext fiscal year
FY EPS (est.)
-$3.35next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Phase 3 AURORA Trial Topline Data Readout | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Restricted Cash Quarterly120.4MTarget: Sufficient to fund planned operations into mid-2027
Phase 3 AURORA Trial Enrollment (Myasthenia Gravis) QuarterlyTarget: Complete enrollment of approximately 100 participants
Phase 2 TRITON Trial Progress (Myositis) QuarterlyTarget: Evaluate first 10 patients to determine path to a pivotal trial
Watch Items
- Topline data readout from the Phase 3 AURORA trial of Descartes-08 in Myasthenia GravisTrigger: First Quarter of 2027Action: Evaluate clinical efficacy (primary endpoint of ≥3-point MG-ADL improvement at Month 4) and safety profile to support BLA filing preparation
- Interim analysis of the Phase 2 TRITON trial in MyositisTrigger: Enrollment and Week 24 evaluation of the first 10 patientsAction: Determine the regulatory and clinical path to a single pivotal trial in myositis
- Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM)Trigger: Ongoing enrollment updatesAction: Monitor safety and early efficacy signals in pediatric patients
Research as of 20 Jun 2026